HYPR

Hyperfine, Inc.

1.34 USD

Last updated Dec 6, 17:33 UTC

Yesterday HIGH

$1.38

Yesterday LOW

$1.29

52w HIGH

$3.28

52w LOW

$0.68

EPS

-0.15

PE

-8.93

Next Earnings

Mar 19, 2024

Overview News Insider Transactions Government Trades

Hyperfine, Inc. stock is up 0.75% since 30 days ago. The next earnings date is Mar 19, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 December’s closed higher than November. 0% of analysts rate it a buy.

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system. The company was incorporated in 2014 and is based in Guilford, Connecticut.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Medical Equipment

Headquarters

-

Website

hyperfine.io

totan@benzinga.com

Thu May 11, 2023

Hyperfine Q1 EPS $(0.17) Misses $(0.13) Estimate, Sales $2.63M Beat $2.10M Estimate

Hyperfine (NASDAQ:HYPR) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 50 percent increase over losses of $(0.34) per share from the same
Benzinga Insights

Thu May 11, 2023

Earnings Scheduled For May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its first quarter.
Benzinga Newsdesk

Wed Mar 22, 2023

B. Riley Securities Maintains Buy on Hyperfine, Lowers Price Target to $2.5

B. Riley Securities analyst Neil Chatterji maintains Hyperfine (NASDAQ:HYPR) with a Buy and lowers the price target from $3.5 to $2.5.
Happy Mohamed

Tue Mar 21, 2023

Hyperfine Q4 EPS $(0.19) Beats $(0.22) Estimate, Sales $1.42M Miss $2.25M Estimate

Hyperfine (NASDAQ:HYPR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 93.04 percent increase over losses of $(2.73) per share from the
Benzinga Insights

Tue Mar 21, 2023

Earnings Scheduled For March 21, 2023

Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.20 per share on revenue of $41.75 million.
Benzinga Insights

Mon Mar 20, 2023

Hyperfine's Earnings: A Preview
Lisa Levin

Mon Mar 13, 2023

Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket

Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.
Happy Mohamed

Tue Feb 28, 2023

Hyperfine, Inc. Receives FDA Clearance For Updated Software To Further Improve Diffusion-Weighted Imaging

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system, today announced the U.S. Food and Drug Administration
Happy Mohamed

Mon Feb 27, 2023

Hyperfine Has Been Granted FDA 510k Clearance For The Swoop Portable MR Imaging System

https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K230208
Michael Horton

Thu Feb 23, 2023

Hyperfine Granted European Patent Titled 'DEEP LEARNING TECHNIQUES FOR SUPPRESSING ARTEFACTS IN MAGNETIC RESONANCE IMAGES'

https://register.epo.org/application?number=EP19762019